Drug Trial Radar · NCT06972875
Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Dec 18, 2025
Primary completion
Jan 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- University of VermontAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is for men with prostate cancer who are experiencing hot flashes due to treatments that lower testosterone. Hot flashes can affect your quality of life and make it harder for patients to continue their treatment, so researchers want to find a better way to manage them. The study is testing a drug called fezolinetant, which might help reduce hot flashes without using hormones. Fezolinetant is a drug that is currently approved for the treatment of hot flashes in menopausal women.
Conditions
- Prostate CA
- Androgen Deprivation Therapy
Interventions
FezolinetantDrug
Participants will receive fezolinetant for 28 days at FDA approved dosing and schedule of 45 mg po (per os/by mouth) once daily for treatment of hot flashes in menopausal women.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction in Hot Flash ScoreTime frame: 28 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Vermont Medical Center
Burlington, Vermont · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.